All In Biotech

Drug Trial Radar · NCT03657797

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

A Phase 2, Randomized, Multicenter, Masked, Parrallel-Group, Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 (3 Doses: 0.021%, 0.042%, and 0.065%) vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Last checked: Nov 19, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 656 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

656

Actual

Start

Aug 1, 2018

Primary completion

Aug 23, 2019

Study completion Aug 23, 2019

Sponsor

Lead sponsor
Nicox Ophthalmics, Inc.Industry
Sponsor type
Industry
First posted
Sep 5, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Three different concentrations of NCX 470 ophthalmic solution (0.021%, 0.042%, and 0.065%) will be compared to latanoprost 0.005% ophthalmic solution.

Conditions

  • Glaucoma, Open-Angle
  • Hypertension, Ocular

Interventions

  • NCX 470Drug

    NCX 470 Ophthalmic Solution

  • Latanoprost 0.005%Drug

    Latanoprost 0.005% Ophthalmic Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Study Eye Mean Diurnal IOP at the Week 4Time frame: Baseline, Week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Texan Eye

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.